In accordance with the results of pre-clinical trials Roscardioinvest got the permit for clinical trials of new tri-leaflet heart valve “Tricardiks”.

New tri-leaflet heart valve developed by Roscardioinvest combines advantages of both mechanical and tissue valves. It also has competitive advantages; one of the main is the true central blood flow which reduces the possibility of thrombosis. And also high speed of opening and closing of valve leaflets which show the best correlation with native valve.